NDA 020148 · Bausch
Migranal
Dihydroergotamine Mesylate · Nasal
Last checked: Nov 19, 2026Latest source record: May 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 8, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
5 Phase 3, 0 recruiting
FAERS reports
829
652 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (see CONTRAINDICATIONS and WARNINGS ).
What it is approved for
From the label in effect Mar 6, 2025.
INDICATIONS AND USAGE Dihydroergotamine Mesylate Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine Mesylate Nasal Spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine.
Mechanism: Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. It also binds with high affinity to serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors, noradrenaline α 2A , α 2B and α 1 receptors, and dopamine D 2L and D 3 receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT 1D receptors. Two current theories have been proposed to explain the efficacy of 5-HT 1D receptor agonists in migraine. One theory suggests that activation of 5-HT 1D receptors located on intracranial blood vessels,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 8, 1997 Original approval · Type 3 - New Dosage Form Review
1 products under this application
- MIGRANAL · DIHYDROERGOTAMINE MESYLATE 0.5MG/SPRAY · SPRAY, METERED, NASAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dihydroergotamine" as an intervention, any sponsor and status, largest first.
- A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of MigrainePivotal-lookingCompleted
Satsuma Pharmaceuticals, Inc.Industry
NCT04940390 · 1,591 participants · Start Jun 30, 2021 · Primary completion Oct 13, 2022
Drug: Dihydroergotamine; Placebo · For: Migraine; Migraine With Aura; Migraine Without Aura
Sites: Chandler, Arizona; Phoenix, Arizona; Tempe, Arizona · 127 sites in all
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of MigrainePivotal-lookingCompleted
Satsuma Pharmaceuticals, Inc.Industry
NCT03901482 · 1,201 participants · Start Jun 24, 2019 · Primary completion Jul 31, 2020
Drug: Dihydroergotamine; Placebos · For: Migraine; Migraine With Aura; Migraine Without Aura
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 117 sites in all
- A Study to Evaluate the Safety of STS101 in the Acute Treatment of MigrainePivotal-lookingCompleted
Satsuma Pharmaceuticals, Inc.Industry
NCT04406649 · 482 participants · Start Sep 14, 2020 · Primary completion Jan 16, 2023
Drug: Dihydroergotamine · For: Migraine; Migraine With Aura; Migraine Without Aura
Sites: Encino, California; Long Beach, California; Los Alamitos, California · 44 sites in all
- Cefalium® Compared to Tylenol® in the Treatment of Migraine AttacksPivotal-lookingSuspended
Ache Laboratorios Farmaceuticos S.A.Industry
NCT02582996 · 336 participants (planned) · Start Apr 2020 · Primary completion Apr 2021
Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.; Acetaminophen · For: Migraine
Sites: Salvador, Brazil; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
Thomas Jefferson UniversityAcademic, hospital or other
NCT00335777 · 64 participants · Start Aug 2006 · Primary completion Dec 2008
Drug: Migranal nasal spray at 1 hour; Migranal nasal spray at 4 hour · For: Migraine
Sites: Philadelphia, Pennsylvania
AllerganAbbVie (ABBV)
NCT01191723 · 54 participants · Start Aug 2010 · Primary completion Sep 2010
Drug: MAP0004; Inhaler Placebo and 2 more · For: Healthy
Sites: Fargo, North Dakota
- Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult VolunteersCompleted
AllerganAbbVie (ABBV)
NCT01199965 · 47 participants · Start Jan 2010 · Primary completion Apr 2010
Drug: MAP0004; IV DHE · For: Healthy Subjects
Sites: Merthyr Tydfil, United Kingdom
Satsuma Pharmaceuticals, Inc.Industry
NCT03874832 · 46 participants · Start Sep 11, 2018 · Primary completion Nov 7, 2018
Drug: Dihydroergotamine · For: Migraine With Aura; Migraine Without Aura; Migraine
Sites: Miami, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective387
- off label use359
- hyperhidrosis356
- nightmare339
- sedation339
- nausea338
- product use in unapproved indication293
- nephrolithiasis252
- migraine79
- treatment failure57
- dyspnoea52
- abdominal pain47
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 16 |
| 2006 | 24 |
| 2007 | 24 |
| 2008 | 20 |
| 2009 | 15 |
| 2010 | 18 |
| 2011 | 26 |
| 2012 | 26 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 9 |
| 2017 | 18 |
| 2018 | 14 |
| 2019 | 26 |
| 2020 | 18 |
| 2021 | 64 |
| 2022 | 70 |
| 2023 | 50 |
| 2024 | 125 |
| 2025 | 84 |
| 2026 | 159 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Migranal (Dihydroergotamine Mesylate)
2024 spending
$925K
Beneficiaries
48
236 claims
Per beneficiary
$19,264
$442.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,297,561 |
| 2021 | $608,440 |
| 2022 | $486,180 |
| 2023 | $552,398 |
| 2024 | $924,650 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
VanderPluym JH, Halker Singh RB, Urtecho M, et al. · JAMA 2021 · Meta-Analysis, Research Support, U.S. Gov't, P.H.S.
- Cluster headache.
Matharu M, Silver N · BMJ Clin Evid 2008 · Systematic Review
- Cluster headache.
Matharu M · BMJ Clin Evid 2010 · Systematic Review
- Intravenous Lidocaine for Acute Pain: A Systematic Review.
Masic D, Liang E, Long C, et al. · Pharmacotherapy 2018 · Case Reports, Systematic Review
- Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
Dafer RM, Tietjen GE, Rothrock JF, et al. · Headache 2024 · Clinical Trial, Phase I, Clinical Trial, Phase III
- Reduced efficacy of sumatriptan in migraine with aura vs without aura.
Hansen JM, Goadsby PJ, Charles A · Neurology 2015 · Clinical Trial, Phase III, Comparative Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.